Qiagen logged a -4.4% change during today's afternoon session, and is now trading at a price of $45.88 per share. The S&P 500 index moved 0.0%. QGEN's trading volume is 3,650,908 compared to the stock's average volume of 1,408,922.
Qiagen trades -12.36% away from its average analyst target price of $52.35 per share. The 13 analysts following the stock have set target prices ranging from $45.0 to $60.0, and on average have given Qiagen a rating of buy.
Anyone interested in buying QGEN should be aware of the facts below:
-
Qiagen's current price is 298.9% above its Graham number of $11.5, which implies that at its current valuation it does not offer a margin of safety
-
Qiagen has moved 5.1% over the last year, and the S&P 500 logged a change of 15.9%
-
Based on its trailing earnings per share of 1.69, Qiagen has a trailing 12 month Price to Earnings (P/E) ratio of 27.1 while the S&P 500 average is 29.3
-
QGEN has a forward P/E ratio of 20.0 based on its forward 12 month price to earnings (EPS) of $2.29 per share
-
Its Price to Book (P/B) ratio is 2.84 compared to its sector average of 3.19
-
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
-
Based in Venlo, the company has 5,700 full time employees and a market cap of $9.95 Billion. Qiagen currently returns an annual dividend yield of 0.5%.
